34,710 Shares in HUTCHMED (China) Limited (NASDAQ:HCM) Purchased by ABC Arbitrage SA

ABC Arbitrage SA acquired a new position in shares of HUTCHMED (China) Limited (NASDAQ:HCM) during the 4th quarter, HoldingsChannel reports. The firm acquired 34,710 shares of the company’s stock, valued at approximately $500,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Public Employees Retirement System of Ohio bought a new position in HUTCHMED in the 3rd quarter worth about $35,000. Blue Trust Inc. grew its position in HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after purchasing an additional 3,057 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in HUTCHMED by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock worth $117,000 after purchasing an additional 2,321 shares during the last quarter. Summit Trail Advisors LLC grew its position in HUTCHMED by 14.4% in the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock worth $189,000 after purchasing an additional 1,647 shares during the last quarter. Finally, Crossmark Global Holdings Inc. bought a new position in HUTCHMED in the 3rd quarter worth about $328,000. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Price Performance

HUTCHMED stock opened at $13.80 on Friday. The firm has a 50 day simple moving average of $14.40 and a 200-day simple moving average of $17.00. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. HUTCHMED has a 12-month low of $12.84 and a 12-month high of $21.92.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research report on Monday, November 18th.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.